Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 2/20 | 0.56 |
| ▸ | SELPLG | Q14242 | 1/20 | 0.56 |
| ▸ | TYR | P14679 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.54 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.54 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7035249 | 1.00 | SELP (0.56) | SELPSELPLGTYRNPC1USP2 | |
| SCHEMBL23479703 | 1.00 | SELP (0.56) | SELPSELPLGTYRNPC1USP2 | |
| SCHEMBL7035257 | 1.00 | SELP (0.56) | SELPSELPLGTYRNPC1USP2 | |
| SCHEMBL23479746 | 1.00 | SELP (0.56) | SELPSELPLGTYRNPC1USP2 | |
| SCHEMBL7030131 | 0.88 | TYR (0.57) | TYR | |
| SCHEMBL7030124 | 0.88 | TYR (0.57) | TYR | |
| SCHEMBL23479673 | 0.88 | TYR (0.58) | TYR | |
| SCHEMBL7030619 | 0.88 | TYR (0.58) | TYR | |
| SCHEMBL7030610 | 0.88 | TYR (0.58) | TYR | |
| SCHEMBL23479694 | 0.88 | TYR (0.58) | TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773127-B2 | Compounds and methods for treating bacterial infections | WASHINGTON UNIVERSITY (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773127-B2 | Compounds and methods for treating bacterial infections | WASHINGTON UNIVERSITY (US) | 2023-10-03 | — | — | US | disclosed |
| US-20210171563-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | WASHINGTON UNIVERSITY (US) | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171563-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | MMP8, ELANE, MPO | SELP 442/4885SELPLG 2884/4885TYR 273/4885 |
| US-11773127-B2 | Compounds and methods for treating bacterial infections | MMP8, ELANE, MPO | SELP 442/4885SELPLG 2884/4885TYR 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.